Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Haematological involvement occurs frequently in childhood onset systemic lupus erythematosus (SLE) with autoimmune haemolytic anaemia occurring in 10%. Conventional treatment includes high-dose steroids. Second line agents used in refractory cases include azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. Rituximab, anti-CD20 monoclonal antibody, is emerging in the treatment of SLE refractory to conventional therapy. We report the successful use of anti-CD20 therapy in the treatment of acute life threatening haemolytic anaemia, complicating childhood onset SLE. We propose that earlier introduction of rituximab may reduce the side effects related to other cytotoxic therapy mainly steroids and cyclophosphamide. However, in view of controversies in the reported side effects of rituximab in childhood onset SLE, multicentred randomised controlled trials are required to determine the long-term efficacy, safety and optimal dosing of rituximab in childhood onset SLE.

Original languageEnglish
Pages (from-to)460-464
Number of pages5
JournalLupus
Volume18
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Hemolytic Anemia
Systemic Lupus Erythematosus
Monoclonal Antibodies
Cyclophosphamide
Steroids
Mycophenolic Acid
Autoimmune Hemolytic Anemia
Azathioprine
Cyclosporine
Therapeutics
Randomized Controlled Trials
Safety
Rituximab

Keywords

  • Childhood onset SLE
  • Haematological abnormalities
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. / Abdwani, R.; Mani, R.

In: Lupus, Vol. 18, No. 5, 2009, p. 460-464.

Research output: Contribution to journalArticle

@article{00ff4d3efb694185a314b1201890bc6e,
title = "Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE",
abstract = "Haematological involvement occurs frequently in childhood onset systemic lupus erythematosus (SLE) with autoimmune haemolytic anaemia occurring in 10{\%}. Conventional treatment includes high-dose steroids. Second line agents used in refractory cases include azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. Rituximab, anti-CD20 monoclonal antibody, is emerging in the treatment of SLE refractory to conventional therapy. We report the successful use of anti-CD20 therapy in the treatment of acute life threatening haemolytic anaemia, complicating childhood onset SLE. We propose that earlier introduction of rituximab may reduce the side effects related to other cytotoxic therapy mainly steroids and cyclophosphamide. However, in view of controversies in the reported side effects of rituximab in childhood onset SLE, multicentred randomised controlled trials are required to determine the long-term efficacy, safety and optimal dosing of rituximab in childhood onset SLE.",
keywords = "Childhood onset SLE, Haematological abnormalities, Rituximab",
author = "R. Abdwani and R. Mani",
year = "2009",
doi = "10.1177/0961203308098360",
language = "English",
volume = "18",
pages = "460--464",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE

AU - Abdwani, R.

AU - Mani, R.

PY - 2009

Y1 - 2009

N2 - Haematological involvement occurs frequently in childhood onset systemic lupus erythematosus (SLE) with autoimmune haemolytic anaemia occurring in 10%. Conventional treatment includes high-dose steroids. Second line agents used in refractory cases include azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. Rituximab, anti-CD20 monoclonal antibody, is emerging in the treatment of SLE refractory to conventional therapy. We report the successful use of anti-CD20 therapy in the treatment of acute life threatening haemolytic anaemia, complicating childhood onset SLE. We propose that earlier introduction of rituximab may reduce the side effects related to other cytotoxic therapy mainly steroids and cyclophosphamide. However, in view of controversies in the reported side effects of rituximab in childhood onset SLE, multicentred randomised controlled trials are required to determine the long-term efficacy, safety and optimal dosing of rituximab in childhood onset SLE.

AB - Haematological involvement occurs frequently in childhood onset systemic lupus erythematosus (SLE) with autoimmune haemolytic anaemia occurring in 10%. Conventional treatment includes high-dose steroids. Second line agents used in refractory cases include azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. Rituximab, anti-CD20 monoclonal antibody, is emerging in the treatment of SLE refractory to conventional therapy. We report the successful use of anti-CD20 therapy in the treatment of acute life threatening haemolytic anaemia, complicating childhood onset SLE. We propose that earlier introduction of rituximab may reduce the side effects related to other cytotoxic therapy mainly steroids and cyclophosphamide. However, in view of controversies in the reported side effects of rituximab in childhood onset SLE, multicentred randomised controlled trials are required to determine the long-term efficacy, safety and optimal dosing of rituximab in childhood onset SLE.

KW - Childhood onset SLE

KW - Haematological abnormalities

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=63749128989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63749128989&partnerID=8YFLogxK

U2 - 10.1177/0961203308098360

DO - 10.1177/0961203308098360

M3 - Article

VL - 18

SP - 460

EP - 464

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -